Multiple Myeloma Market Top Companies, Overview & Key Products

Download this Free Sample Now and Get the Complete Report and Insights of this Market Easily @ https://www.towardshealthcare.com/download-sample/5489

Top 10 Leading Companies in Multiple Myeloma Market

1. Bristol-Myers Squibb (BMS)

Strengths: Strong oncology portfolio, innovative CAR-T therapies, extensive R&D investment. Key Products: • Revlimid (Lenalidomide) – an immunomodulator widely used in multiple myeloma. • Empliciti (Elotuzumab) – monoclonal antibody targeting SLAMF7. • Abecma (Idecabtagene vicleucel) – first FDA-approved CAR-T cell therapy for multiple myeloma.

2. Amgen Inc.

Strengths: Leading biopharmaceutical company with strong biologics pipeline, robust global presence. Key Products: • Kyprolis (Carfilzomib) – a proteasome inhibitor used in relapsed multiple myeloma. • Blincyto – though mainly for leukemia, reflects Amgen’s immunotherapy strength.

3. Johnson & Johnson (Janssen Pharmaceuticals)

Strengths: Extensive oncology portfolio, strong marketing and distribution network, strong R&D pipeline. Key Products: • Darzalex (Daratumumab) – CD38-targeting monoclonal antibody for multiple myeloma. • Imnovid (Pomalidomide) – immunomodulatory drug.

4. Takeda Pharmaceutical Company

Strengths: Focus on hematology and oncology, strong pipeline and collaborations, significant global footprint. Key Products: • Velcade (Bortezomib) – pioneering proteasome inhibitor in multiple myeloma treatment. • Ninlaro (Ixazomib) – oral proteasome inhibitor.

5. Novartis AG

Strengths: Broad oncology portfolio, innovative drug development, global reach. Key Products: • Pomalyst (Pomalidomide) – immunomodulatory drug. • Kymriah – CAR-T therapy platform (primarily for other cancers but reflects tech capability).

6. Sanofi S.A.

Strengths: Strong research and development, diverse pharmaceutical portfolio, strategic acquisitions. Key Products: •Sarclisa (Isatuximab) – monoclonal antibody targeting CD38. • Myozyme – showcases Sanofi’s biologics expertise.

7. Celgene (now part of Bristol-Myers Squibb)

Strengths: Former leader in immunomodulators and targeted therapies, now integrated with BMS’s oncology arm. Key Products: • Revlimid (Lenalidomide) – flagship drug for multiple myeloma treatment.

8. GSK (GlaxoSmithKline)

Strengths: Strong in immunotherapies and monoclonal antibodies, extensive global distribution. Key Products: • Blincyto (Blinatumomab) – bispecific antibody (more leukemia-focused but indicates immune therapy strength).

9. Regeneron Pharmaceuticals

Strengths: Cutting-edge monoclonal antibodies and immunotherapy, robust R&D in oncology. Key Products: • Libtayo (Cemiplimab) – PD-1 inhibitor with potential applications. • Pipeline focused on immuno-oncology, including multiple myeloma.

10. Karyopharm Therapeutics

Strengths: Specialized focus on cancer therapies, innovative drug candidates, growing presence in multiple myeloma. Key Products: • XPOVIO (Selinexor) – first-in-class nuclear export inhibitor approved for multiple myeloma.

Fill the given form below and get the complete report immediately Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5489 Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: https://www.towardshealthcare.com/access-dashboard Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting You can place an order or ask any questions, please feel free to contact us at [email protected]